36455-72-8
基本信息
Α-玉米赤霉烯醇
ALPHA-玉米赤霉烯醇
Α-玉米赤霉烯醇 標(biāo)準(zhǔn)品
ALFA-ZEARALENOL
Α-玉米赤霉烯醇溶液,100PPM
Α-玉米赤霉烯醇溶液,1000PPM
乙腈中Α-玉米赤霉烯醇溶液,100ΜG/ML
2,4-二羥基- 6-(6Α,10-二羥基反式-)苯甲酸Μ-內(nèi)酯
ALPHA-2,4二羥基- 6 - [10 -二羥基- 1 - 十一碳烯基]苯甲酸酯
Α-ZEARALENOL
A-ZEARALENOL
(3S,7R,11E)-
alfa-Zearalenol
ALPHA-ZEARALENOL
Zearalenol, alpha-
trans-α-Zearalenol
α-Zearalenol solution
alpha-Zearalenol solution
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表
α-Zearalenol (α-zol) (0.001-10 μM; 24-72 hours) shows the highest RPE (90.5%) at 9.37 μM α-ZOL exposure in MFC-7 cells with an IC 50 of 12.5 μM. α-Zearalenol (α-zol) (0.001-10 μM; 24-72 hours) induces an increase of cell viability on MCF-7 cells mainly after 72 h of treatment whereas it is slightly cytotoxic on MDA-MB231 cells. α-Zearalenol (α-zol) (0.001-10 μM; 24-72 hours) increases MCF7 cell population in the S phase and in the G2/M phase, no visible change in cell cycle phases is observed in MDA-MB231 cells. α-Zearalenol (α-zol) (1-10 μM; 24 hours) reduces the expression of TNF-α, α-ZOL combines with β-ZOL shows an antagonistic effect on inflammation for IL-1β and act synergic for IL-8 at high toxin concentrations.
Cell Proliferation Assay
Cell Line: | MFC-7 cells |
Concentration: | 6.25 μM-25 μM |
Incubation Time: | 24 hours |
Result: | Observed the highest RPE (90.5%) at 9.37 μM α-ZOL exposure in MFC-7 cells. |
Cell Viability Assay
Cell Line: | Breast cancer cell lines: MCF-7 and MDA-MB231 |
Concentration: | 0.001 μM, 0.1 μM and 10 μM |
Incubation Time: | 24 hours, 48 hours, 72 hours |
Result: | Modified the cell growth in two breast cancer cell lines. |
Cell Cycle Analysis
Cell Line: | MCF7 cells, MDA-MB231 cells |
Concentration: | 0.001 μM, 0.1 μM and 10 μM |
Incubation Time: | 72 hours |
Result: | Observed an increase of cells in cell cycle in MCF7 cells. |
RT-PCR
Cell Line: | HepG2 cells |
Concentration: | 1 μM, 5 μM, 10 μM |
Incubation Time: | 72 hours |
Result: | Induced a decrease of the expression of TNF-α, IL-1β and IL-8, that was in most cases statistically significant for the higher doses. |